Benefits from $4.3 Million in Investments Tied to State’s Angel Investor Tax Credit Program
 

STOPit Chief Financial Officer Parkhill Mays calls Angel Investor Tax Credit Program “catalyst to fuel continued investment"

TRENTON (February 18, 2016) – Bedminster-based technology company STOPit is receiving national attention for its technology platform that lets people report bullying, both traditional and cyber, and other forms of inappropriate behavior in schools, universities and places of employment.

STOPit’s software enables users to instantly and anonymously report incidents via their smartphones or computers. STOPit puts power in the hands of anyone who witnesses an incident, enabling users to take screenshots or videos of the situation in question and pass information along to the school or business. It also allows for two-way communication between the user and the entity to which the incident is being reported, while maintaining the anonymity of the user.

“STOPit is a simple, fast and powerful solution to report inappropriate behaviors, and to deter unethical or illegal activity,” STOPit Chief Financial Officer Parkhill Mays said. “Young people are apprehensive about being labeled as ‘snitches.’ Our technology allows them to anonymously report incidents of bullying or other inappropriate behavior they witness without the threat of retaliation.”

The company has been recognized by national media outlets for its platform, which is currently available for Android and Apple phones. CBS News wrote, “Watch out, cyberbullies: Kids have new tools to fight back” and CNN described STOPit as one of “5 Apps To Help Change The World.” The New Jersey Technology Council gave STOPit the Trailblazer Award at its annual awards celebration in November.

STOPit received more than $4.3 million in funding from investors who took advantage of the State’s Angel Investor Tax Credit Program in 2015. Administered by the New Jersey Economic Development Authority (EDA) in consultation with the New Jersey Division of Taxation, the Angel Investor Tax Credit Program offers a 10 percent refundable tax credit against New Jersey corporation business or gross income tax for qualified investments in an emerging technology business with a physical presence in New Jersey and that conducts research, manufacturing, or technology commercialization in the state. The program is available to all eligible taxpayers, including out-of-state investors.

The EDA recently announced that more than $125 million has been invested in New Jersey-based emerging technology and biotechnology businesses through the Angel Investor Tax Credit Program since its inception in 2013. In 2015 alone, 213 Angel Investor Tax Credit applications were approved to support 28 emerging technology and life sciences companies in the Garden State, representing the investment of over $50 million of private capital.

@NJEDATech spoke with Mays about STOPit’s experience in New Jersey and its plan for the future:

What does STOPit find most beneficial about locating itself in New Jersey?
Our location in New Jersey was initially convenient to several of our founders. However, we soon realized that our location is ideally positioned and in close proximity to the best professional resources suitable to our mission. Furthermore, we are right smack in the middle of a very dense supply of talented people who share our values and who desire to work with STOPit.

How has the Angel Investor Tax Credit Program helped the company?
The Angel Investor Tax Credit has provided a meaningful boost in value to our shareholders.  When first introduced to the program, we were astonished that such a gift existed, and our shareholders were pleasantly surprised. Additionally, since we are still raising capital, the program has been one of the catalysts to fuel continued investment in STOPit by existing shareholders.

What is STOPit’s biggest success to date?
Our biggest success to date has been the overwhelming response to our product. We have been able to offer software that protects kids and other users, and provides institutions with an immediate alert and window into a problem so that they can get out in front of issues and address them before they spiral out of control.

What’s on the horizon for the company?
We are rapidly infiltrating the K-12 education market now, which enables us to protect even more students. We have just released our workplace product, and expect our solution to be adopted rapidly by government agencies and risk-management and compliance personnel from the nation’s largest companies.

To learn about programs and initiatives that support New Jersey’s technology industry, visit https://www.njeda.gov/tls and follow @NJEDATech on Twitter and LinkedIn.
 

A Camden Economic Recovery Board Meeting will take place at 10:00 a.m. on Thursday, February 18, 2016  at the Waterfront Technology Center, 200 Federal Street, Camden, NJ 08102.

A copy of the proposed agenda can be found prior to the meeting at https://www.njeda.gov/public_information/erb/agenda.

Following the Board Meeting, minutes will be available at https://www.njeda.gov/public_information/erb/minutes.

The New Jersey Economic Development Authority (EDA) recently unveiled its second group of Executive-in-Residence (EIR) appointees. These highly-skilled life sciences professionals will mentor and advise emerging companies at EDA’s Commercialization Center for Innovative Technologies (CCIT) in North Brunswick. The EIR program was created in collaboration with BioNJ.  

Over the next few weeks, @NJEDATech will continue to delve into the back-stories of these EIRs; next up is Rick Winneker, of Margate.
 

 
Rick Winneker (Executive-in-Residence – Research Communications, Strategic Planning and Partnering) brings 30 years of experience, specializing in drug discovery and development, and life sciences research and organizational strategic planning to his mentorship role at CCIT. Throughout his career, Winneker has worked in all phases of research and development, including building pharmaceutical research organizations. He has shaped, and led, several pharmaceutical research departments in endocrinology and women’s health that resulted in 14 compounds being delivered to the development pipeline along with four registered products. While Winneker plans to focus his mentoring role on research communications, strategic planning and partnering, he looks forward to sharing his knowledge on a broad array of areas with tenants at the life sciences incubator.
 
Winneker will deliver a presentation at CCIT to the technology community on February 12 at noon about strategies to get funding and other helpful resources from disease foundations such as The Leukemia & Lymphoma Society and many others. 
 
Prior to becoming an EIR, Winneker spent five years as a Senior Vice President at the Leukemia & Lymphoma Society, building and leading a research group focused on the goal of improving the standard of care and accelerating cures for patients with blood cancers. He also worked for nearly 15 years at Wyeth Research, spearheading a drug discovery group focused on contraception, menopausal symptoms and reproductive disorders in women.
 
Winneker earned a Bachelor of Science degree from Penn State University, a Master of Science degree in physiology from University of Illinois at Urbana-Champaign, and a PhD in anatomy from the University of Minnesota.
 
Although he has just started in his role at the life sciences incubator, he has already met with numerous tenant companies, including SunGen Pharma, Grace Therapeutics, Ascendia Pharmaceuticals, Shionogi Inc., Bellerophon Therapeutics and Nexomics Biosciences.
 
@NJEDATech asked Winneker about the Executive-in-Residence Program and his plans for the future:
 
Why did you choose to apply to the Executive-in-Residence program?
While looking for my next full time job, I like to keep busy and contribute to the life sciences community. I’m pleased to be doing some consulting work and volunteering my time while actively networking. It was Vicky Gaddy from BioNJ that brought the opportunity at CCIT to my attention.  I really enjoy advising, coaching and mentoring other scientists and entrepreneurs, so this looked like a great chance to do just that. 
 
What do you hope to get out of this Executive-in-Residence program?
I hope to use my extensive experience to help some of these new companies and their leaders succeed in any way that I can, whether it be to raise money, make new contacts, build better strategic plans or simply sharpen their communications.  I am also looking forward to meeting new people, expanding my job seeking and personal network and becoming more familiar with the biotech startup community in this region of New Jersey. I am pleased to say that I have already met many interesting people during my visits to CCIT including the other new EIRs and have participated in several EDA events. 
 
What’s the best piece of advice you’ve heard over the years that you hope to impart on these emerging life sciences companies?
I would offer two pieces of advice.  First, while it is extremely important to work hard and be passionate about your science and your company, you shouldn’t forget to have some fun, enjoy the experience and be sure to save time for your family and kids. Your children grow up very fast and you can’t get that time back.  Second, don’t forget that even great science can’t overcome bad management and poor planning. It’s critical that you have the right people in place at the right time to lead your company.  I have seen too many examples of poor management killing a great scientific opportunity or delaying its implementation. This is one place where the EIRs can help. 
 
What is the next challenge you want to undertake in your career?
Ideally, I would love to find a leadership position in a biotech life sciences company.  While I have worked closely with many biotech companies over the years, both while leading a research organization in big pharma and as a funder and strategic partner at a disease foundation, becoming a member of the biotech leadership team would represent a new and welcome challenge for me. I feel my skills would lend great value to the right biotech company. Having said that, I am open to any opportunity where I can work with great people in an area of science and medicine that can truly have a positive impact on the lives of patients and their families. 
 
More information about EIR program, including eligibility, can be found at www.njeda.gov/EIR.

To learn about programs and initiatives that support the technology industry, visit https://www.njeda.gov/tls and follow @NJEDATech on Twitter and LinkedIn.

Conveyor Curve (Belt) Company Supports Critical Industries

TRENTON, N.J. (February 9, 2016) – Flow-Turn Inc., a Union Township-based global manufacturer of powered belted curve conveyors, was highlighted at today’s  New Jersey Economic Development Authority (EDA) Board meeting for the approval of a loan the company received through the Premier Lender Program.

The $1.5 million Fulton Bank loan, which includes a $400,000 EDA participation, will allow Flow-Turn to refinance the mortgage on its 35,000-square-foot warehouse and office facility. The EDA partners with more than 30 Premier Lender banks to provide small businesses with low cost financing that includes loan participation and/or guarantees, and faster turnaround than traditional financing programs. Businesses can use Premier Lender financing for fixed assets, working capital to meet operating needs, or the refinancing of bank debt.

“Manufacturing companies like Flow-Turn not only create skilled jobs, but are an essential link in the supply chain of companies in many industries,” said EDA CEO Melissa Orsen. “Flow-Turn’s products support parcel and baggage handling, distribution, and factory automation, all of which are critical to both the State and global economies.”

The company expects to maintain its staff of 18 and create an additional six new full-time jobs.

Another Union County manufacturer, metal hose assembly producer Flexline, was previously approved for a $1.35 million Premier Lender loan through PNC Bank, backed by a 25 percent EDA guarantee.  The loan supported the acquisition of a commercial building in Kenilworth.

Flexline is currently featured in publications throughout the State as part of the EDA’s new small and mid-sized business-focused print and digital marketing campaign, which was created in collaboration with Princeton Partners, Inc.  Launched in October 2015, and featuring the theme “EDA Was Here,” the campaign anecdotally showcases how businesses like Flexline have used the EDA’s financing programs to overcome challenges, meet their needs and grow. The campaign consists of print ads in various New Jersey business publications, as well as search engine marketing and digital display ads on various business websites.  

“We encourage business owners to contact us to learn more about how the State can help them thrive,” added Orsen. “From low interest loans either directly or through one of EDA’s lending partners, to training and technical assistance services to support the expansion and long-term growth of small businesses and not-for-profit organizations, the array of resources offered is available to help businesses in all stages of growth.”

The EDA often partners with financial institutions, local organizations and other State agencies to help borrowers bridge financing gaps and increase their access to capital. This includes offering low-interest loans, bond financing, and support for micro-lenders to increase their lending capacity and the technical assistance and training services they offer.  In 2015 alone, the EDA supported over 90 projects with more than $357 million in assistance, leveraging an estimated $532 million in total public/private investment and the creation of more than 1,100 new jobs across the State.

The EDA is part of the state’s results-driven Partnership for Action. Created by Governor Christie and led by Lt. Governor Guadagno, the Partnership is the hub for all economic development activity in New Jersey and is comprised of four interconnected and highly focused organizational elements: Choose New Jersey, the Business Action Center, the Office of the Secretary of Higher Education and the EDA. 

To learn more about opportunities for business growth throughout New Jersey, visit the state’s business portal at www.NewJerseyBusiness.gov or call the Business Action Center at (866) 534-7789.

TRENTON (February 5, 2016) – As the country celebrates “National Wear Red Day” today to raise awareness about heart disease, @NJEDATech takes a look at several New Jersey Economic Development Authority (EDA)-supported companies that strive to improve the lives of cardiac patients. According to the American Heart Association, heart disease and stroke cause one in three deaths among women each year, killing approximately one woman every 80 seconds. 
 
“The statistics on heart disease are sobering,” EDA Chief Executive Officer Melissa Orsen said. “However, the progress that EDA-supported startup companies are making toward stemming the tide of heart disease is promising.  From implantable medical devices to injectable drugs, these companies continue to create industry-leading, impactful products.”
 
Svelte Medical Systems, located in New Providence, produces a cost-effective integrated balloon expandable drug eluting coronary stent system featuring the smallest diameter in the industry. This stent, which is now approved in Europe and will undergo United States studies later this year, has led to a new standard of care in treating the buildup of plaque in coronary arteries, known as atherosclerosis. The company was founded by industry leading scientists — physicist Dr. Robert Fischell and his sons Dr. David Fischell, also a physicist, and Dr. Tim Fischell, an interventional cardiologist.
 
The Fischells also founded Angel Medical Systems, located in Shrewsbury. The company developed an implantable device, known as the AngelMed Guardian® System that can detect the onset of a heart attack and alert patients to quickly seek medical attention. The Guardian® is under final review for approval by the United States Food and Drug Administration this year.
 
Svelte Medical Systems and Angel Medical Systems are among the more than 500 companies that have benefitted from the State’s Technology Business Tax Certificate Transfer (NOL) Program. The program allows qualified technology and biotechnology companies to sell unused New Jersey net operating losses and research and development tax credits to unrelated profitable corporations to raise cash to finance their growth and operations. Svelte Medical Systems also raised millions of dollars from investors who took advantage of the State’s Angel Investor Tax Credit Program, which provides credits against New Jersey corporate business or gross income tax for 10 percent of a qualified investment in an emerging technology business that conducts research, manufacturing, or technology commercialization in the state. 
 
VEESAG Mobile develops wearable technology aimed at helping people maintain their independence, remain healthier and live better. The company’s smart watch, Mobile Personal Emergency Response System (MPERSENS®), comes equipped with an application for heart monitoring and a one-touch emergency button, as well as location tracking, fall detection, and remote monitoring. It can also share critical information with family members. Following confirmation in 2015 from Sprint and Verizon that the devices were compatible with their networks, VEESAG Mobile is ramping up manufacturing to make its watches widely available to consumers.
 
Ascendia Pharmaceuticals is developing ASD-002, an injectable form of the blood thinner clopidogrel, the generic form of Plavix®, which is currently administered orally. Ascendia expects ASD-002 to be utilized in multiple markets, including catheterization procedures, peripheral arterial disease and acute coronary syndrome. The company is currently preparing for clinical testing of ASD-002.
 
VEESAG Mobile and Ascendia Pharmaceuticals are both located at the EDA’s Commercialization Center for Innovative Technologies (CCIT). Nestled among commercial real estate up and down the Rt. 1 corridor in North Brunswick, CCIT is New Jersey’s leading life sciences incubator. Home to nearly two dozen seed-stage life sciences companies, CCIT offers its tenants not only affordable lab and office space, but also a wealth of resources, such as assistance with identifying funding sources, including state incentives, and help making matches to private sector support, discounted rent for the first year for university spinouts, access to small business development resources and administrative support.

The New Jersey Economic Development Authority's next public Board Meeting will be held on Tuesday, February 9, 2016 at 10 a.m. at the EDA offices at 36 West State Street, Trenton. A copy of the proposed agenda can be found prior to the meeting at www.njeda.gov/Board. Following the Board Meeting, minutes and the full agenda will also be available at www.njeda.gov/Board.

The New Jersey Economic Development Authority (EDA) recently unveiled its second group of Executive-in-Residence (EIR) appointees. These highly-skilled life sciences professionals will mentor and advise emerging companies at EDA’s Commercialization Center for Innovative Technologies (CCIT) in North Brunswick. The EIR program was created in collaboration with BioNJ.  

Over the next few weeks, @NJEDATech will continue to delve into the back-stories of these EIRs; next up, Roland Staal, of Metuchen.
 

 
Roland Staal (EIR – Strategic and Product Planning) is a scientist with a passion for drug discovery. He particularly enjoys understanding how drugs work and identifying new targets and strategies for developing desperately-needed therapeutics.
 
Staal graduated with a Bachelor of Science degree from Rutgers University and a PhD in Pharmacology from Rutgers University – UMDNJ – Robert Wood Johnson Medical School. His academic career at Rutgers-UMDNJ, as well as the time he spent at Columbia University as a post-doctoral fellow and then as an associate research scientist, focused on investigating various molecular mechanisms that contribute to Parkinson’s disease.
 
Staal subsequently joined Wyeth Research (now part of Pfizer) where he worked on drug discovery projects for Parkinson’s disease and Alzheimer’s disease. Most recently, Staal served as a principal scientist for Lundbeck Research, a mid-sized pharmaceutical company that conducts brain disease research. At Lundbeck, Staal was instrumental in the creation of the neuroinflammation department, tasked with developing treatments for chronic pain.
 
During his time in the industry, Staal served as the biology team leader and project leader for various pre-clinical drug discovery projects for indications including Parkinson’s disease, Alzheimer’s disease as well as neuropathic pain. He assisted in evaluating in-licensing opportunities and coordinated collaborations with internal departments, academic labs, and contract research organizations. Staal’s comprehensive knowledge of the pharmaceutical industry, licensing opportunities and experience managing projects position him as an ideal mentor to many of the CCIT tenants currently developing and commercializing lifesaving therapies.
 
@NJEDATech asked Staal about the Executive-in-Residence Program and his plans for the future:
 
Why did you choose to apply to the Executive-in-Residence Program?
I initially heard about the CCIT and the EIR program from Vicky Gaddy at BioNJ and was immediately intrigued by the opportunity to mentor/advise nascent start-up companies. I have always been curious to learn about new and innovative technologies and ideas, and am always been eager to take on new challenges. Furthermore, I have always enjoyed mentoring interns and sharing knowledge with collaborators. Thus, this seemed to be a great opportunity to learn about some of the exciting start-up companies in NJ as well as share some of my experience regarding project strategy and planning.
 
What do you hope to get out of this Executive-in-Residence Program?
Networking was often mentioned as one of the benefits of the EIR program and this was important to me, as I wanted to steer my career in a different direction while remaining in NJ. I also want to learn more about some of the State’s novel technologies and start-up companies. During the time that I have been at CCIT, I have met a number of very interesting people: from EDA staff, to fellow EIRs, tenant companies and CCIT advisory board members. Through these people, I have made many connections to organizations and people with common interests working on very different and exciting projects.
 
What’s the best piece of advice you’ve heard over the years that you hope to impart on these emerging life sciences companies?
Do what you love, delegate the rest! The person who gave me this advice was joking, but at the same time completely earnest. In various points of our careers and life, we have to do what needs to be done, even if that means going out of our comfort zone. One has to be flexible, and always willing to learn. This is especially true for new projects and start-up companies. However, once you gain momentum and grow as a start up, group or organization — delegate. Especially delegate the tasks that drain your productivity and slow down your momentum. It is still important to know how to do a given task, to understand how it fits in with your goal, but if someone else can do it better or more efficiently, delegate. This frees up your time to do what you are best at or what you are passionate about.
 
What is the next challenge you want to undertake in your career?
The next challenge I am looking to undertake is to build on my preclinical drug discovery experience by learning more about clinical trials. I am very interested in translational medicine and clinical trials in order to gain experience in the entire drug discovery process, from the initial concept through United States Food and Drug Administration approval and post marketing surveillance. Alternatively, I would also be very interested in working with others to start a new biotech company or joining a start-up company to learn the business of bringing technologies or novel therapeutics to the market.
 
More information about EIR program, including eligibility, can be found at www.njeda.gov/EIR.

To learn about programs and initiatives that support the technology industry, visit https://www.njeda.gov/tls and follow @NJEDATech on Twitter and LinkedIn.

Morris Plains-based Immunomedics is developing drugs designed to combat certain types of cancers with the potential to prolong patients’ lives

TRENTON (January 28, 2016) – Exemplifying the way New Jersey’s innovative ecosystem is impacting the scientific world, Morris Plains-based Immunomedics is developing drugs designed to combat certain types of cancers with the potential to prolong patients’ lives. The biopharmaceutical company has tapped into the State’s popular Technology Business Tax Certificate Transfer Program (NOL) Program over the years to further its goal.

Immunomedics is creating drugs that target aggressive types of cancerous solid tumors, such as triple-negative breast cancer, lung cancer, pancreatic cancer and colorectal cancer. These therapies are designed for patients who have not responded favorably to previous lines of treatment. Immunomedics’ portfolio of investigational products includes antibody-drug conjugates (ADCs), which are designed to deliver a chemotherapeutic selectively to the tumor while reducing overall toxic effects usually found with conventional administration of this type of therapy.

The U.S. Food and Drug Administration (FDA) awarded Fast Track status last year to Immunomedics’ lead ADC, sacituzumab govitecan (IMMU-132), for the treatment of patients with metastatic non-small cell lung cancer. The FDA previously granted Fast Track status to IMMU-132 for the therapy of patients with triple-negative breast or small-cell lung cancers. IMMU-132 has also been designated an orphan drug by the FDA for the treatment of patients with small-cell lung or pancreatic cancers.

“In a Phase 2 clinical trial, IMMU-132 has produced encouraging results in patients with advanced solid cancers that include triple-negative breast, small-cell and non-small-cell lung cancers, esophageal, urinary bladder, and other epithelial cancers,” said Peter P. Pfreundschuh, Immunomedics Chief Financial Officer and Vice President of Finance.

Immunomedics has benefited repeatedly from the NOL Program. Administered by the EDA and the New Jersey Department of Treasury's Division of Taxation, this competitive program enables eligible technology and biotechnology companies to sell New Jersey tax losses and/or research and development tax credits to raise cash to finance their growth and operations. Since the program’s inception in 1999, more than 500 technology and life sciences companies have received a total of more than $860 million.

Pfreundschuh was present at a recent HealthCare Institute of New Jersey (HINJ) roundtable discussion that touched upon resources available to the Garden State’s pharmaceutical industry. During the discussion, Pfreundschuh told New Jersey state leaders what a difference the NOL program has meant to his company.
“The $5.1 million cash proceeds from the NOL program have allowed us to continue with our aggressive agenda to advance a currently ongoing Phase 3 pivotal study in patients with advanced pancreatic cancer, and support the ongoing clinical trials with our ADC,” he said.

@NJEDATech asked Pfreundschuh about Immunomedics’ experience in New Jersey and its plans for the future:

What advantages does Immunomedics see in locating itself in New Jersey?
We have found numerous advantages to locating our headquarters in New Jersey. In terms of human resources, New Jersey has a highly educated workforce trained in science and technology, from which we can recruit. In addition, the State is home to a significant number of multinational pharmaceutical and biotechnology companies for potential scientific collaborations and commercial licensing. Finally, resources such as the NOL program provide small, unprofitable biotechnology companies like ours with an important source of non-dilutive financing to fund our working capital needs.

What is Immunomedics’ biggest success to date?
We have pioneered a new approach in cancer therapy using ADCs that are different from the current industry paradigm.  We’re very encouraged by the Phase II results of IMMU-132 in a variety of solid tumors. Patients enrolled in this program have had many prior therapies, and have limited options to treat their cancer. Based on these promising results, IMMU-132 was recently recognized as one of the “Most Promising Clinical Candidates” at the recent World ADC Awards in San Diego.

What’s on the horizon for the company?
Our main focus currently is to consummate a licensing partnership with large pharma or biotech to advance IMMU-132 to a Phase 3 registration trial in patients with metastatic triple-negative breast cancer. Trial design, including a Special Protocol Assessment agreement, with the FDA has been completed. Clinical materials for the Phase 3 study and beyond are being prepared and tested by outside manufacturers.

Our second ADC, labetuzumab govitecan (IMMU-130), has completed a Phase 2 study in patients with metastatic colorectal cancer. Plans for a Phase 3 study in this indication are underway. In addition, the pivotal Phase 3 clinical trials of yttrium-90-(90Y)-labeled clivatuzumab tetraxetan in patients with relapsed, advanced pancreatic cancer is expected to complete patient enrollment in 2016, with results anticipated shortly thereafter.

For more information about resources available to support New Jersey’s technology industry, visit https://www.njeda.gov/tls and follow @NJEDATech on Twitter and LinkedIn.
 

News Release –  NEW JERSEY DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT

New Jersey Unemployment Falls to 5.1 Percent, Within 0.1 Percent of National Rate
64,500 Private Sector Jobs Added in 2015 Represents Strongest Growth in 15 years 

TRENTON, N.J., January 21, 2016 – New Jersey's private sector employers reported another month of solid growth in December, adding 12,500 jobs to bring the total private sector employment increase for 2015 to 64,500 jobs.  This affirms 2015 as the strongest year of private sector job growth in 15 years and the sixth consecutive year of private sector growth in the Garden State, according to preliminary monthly data released by the United States Bureau of Labor Statistics (BLS).
 
New Jersey's unemployment rate continued to tumble, dropping by 0.3 percentage points in December to 5.1 percent, off the national rate by 0.1 percent and down 4.7 percentage points since the recessionary high of 9.8 percent in January 2010. Total nonfarm employment rose by 13,300 jobs over the month to reach a seasonally adjusted total of 4,047,500 as measured by the BLS through its monthly employer survey. The number of residents reporting to have jobs in New Jersey reached an historic level for the fourth time in 2015, climbing to an all-time high of 4,332,900 in December after reaching a record 4,300,700 in November, according to the BLS household survey.

Read more